alnuctamab

Alnuctamab is a bispecific monoclonal antibody designed as a T-cell engager for the treatment of relapsed and/or refractory multiple myeloma. It targets both the B-cell maturation antigen (BCMA; TNFRSF17) on malignant plasma cells and CD3 on T cells, facilitating T cell-mediated cytotoxicity against BCMA-expressing myeloma cells[1][4][5][6]. Alnuctamab has demonstrated antitumor activity in preclinical and early clinical studies, with ongoing trials evaluating its safety and efficacy in patients who have failed prior therapies[4][6][7]. The drug was originally developed by EngMab and further developed by Celgene Corporation, now part of Bristol Myers Squibb[5]. Clinical development has included both intravenous and subcutaneous formulations, with subcutaneous administration showing improved safety profiles regarding cytokine release syndrome (CRS)[4].

Other names

alnuctamab